Millipore To Open Training Facility in Singapore Next Year
Millipore plans to open a new applications and training facility in Singapore, the company announced this week.
The facility is intended to cater to biotech customers operating in Asia. Millipore President and CEO Martin Madaus announced the move during his visit to Singapore, Beijing, and Tokyo for the Bioforum Asia conference.
The facility, to be located in Singapore’s Science Park, is expected to open early in 2009. The company said it will provide technical support for biopharmaceutical manufacturing, including tools for investigating, exploring, and optimizing separation, purification, and monitoring.
“Many of our large, multinational customers and local manufacturers have made significant investments in Asia, and this new facility continues and enhances the local support that we have provided over the past 25 years we have been in Singapore,” Madaus said in a statement.
GE Healthcare Adds Financing, Facility Relocation to Asset-Management Offering
GE Healthcare said this week that it has expanded its Scientific Asset Service program to include options for instrument financing and facility relocation.
The company said that the new financing option will allow customers to lease single instruments or to finance entire laboratories. Customers can also obtain loans or enter into sale and leaseback arrangements, GE said.
The company said it will also help customers ensure that facility relocations are “undertaken within agreed timeframes and to exacting standards, meeting specific laboratory process requirements.”
“GE Healthcare is leveraging its reach to offer an unparalleled array of services to laboratories through one provider,” said Bob Moore, services commercial leader at GE Healthcare Life Sciences, in a statement.
Other large tool vendors, including Agilent, Thermo Fisher Scientific, and PerkinElmer have launched similar asset-management programs with the goal of providing customers with a single point of contact for support and services.
Invitrogen to Validate Reagents on Tecan, BMG Labtech Platforms
Invitrogen said this week that it has inked two new agreements, one with Tecan and another with BMG Labtech, to study and validate its reagents with the companies’ microplate instruments.
Under the terms of both of the agreements, announced separately, Invitrogen will work with the companies to develop and promote joint applications to market to pharmaceutical companies.
In the agreement with Tecan, Invitrogen will validate the compatibility of its reagents with Tecan’s microplate detection tools.
Specifically, the companies will validate Invitrogen’s drug discovery reagents on the Tecan Infinite series readers, and on assay systems for key target classes, including Invitrogen’s LanthaScreen TR-FRET for protein kinases, the GeneBLAzer reporter-gene technology for G protein-coupled receptors, and the Adapta assay system for lipid kinases, as well as the PolarScreen FP technology for nuclear receptors.
Under the BMG Labtech agreement, Invitrogen will test its reagents with certain of the company’s readers, as well as its PHERAstar and Omega series instruments.
Stem Cell Screening Facility for Brain Tumors Opens in Australia
The Australian Cancer Research Foundation Brain Tumor Research Center has opened at the University of Queensland’s Queensland Brain Institute, the school announced this week.
Funded by a $1.14 million grant from the Australian Cancer Research Foundation, the new screening facility uses a combination of advanced techniques to record molecular changes in neural stem cell assays. Scientists from QBI, the Institute for Molecular Bioscience, and the Queensland Institute for Medical Research, as well as research clinicians from Brisbane’s leading public hospitals will all have access to the ACRF Brain Tumor Research Center.
Unidym, PrimeGen Ink Deal to Develop Apps for Nanotubes in Stem Cell Research
PrimeGen Biotech and Unidym this week announced a corporate alliance focused on exploring new applications for carbon nanotubes in stem cell medicine.
PrimeGen said that it has successfully used non-viral technologies to reprogram adult human cells into stem cells that the company refers to as intermediate induced pluripotent stem cells.
PrimeGen will have access to Unidym's extensive patent portfolio, services, and industry standard high pressure CO conversion carbon nanotubes.
PrimeGen has submitted its scientific findings, as abstracts, for presentation at the International Society of Stem Cell Research meeting to be held June 11-14 in Philadelphia, Pa.